Compounds > nelfinavir
Page last updated: 2024-08-24

nelfinavir and darunavir

nelfinavir has been researched along with darunavir in 27 studies

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (48.15)29.6817
2010's11 (40.74)24.3611
2020's3 (11.11)2.80

Authors

AuthorsStudies
Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB1
Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX1
Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE1
Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT1
Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A1
Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P1
Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L1
DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI1
Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B1
Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J1
Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H1
Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y1
Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP1
Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Agrawal, N; Chmielewski, J; Hrycyna, CA; Lan, J; Rowe, J; Yu, Q1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R1
Louis, JM; Sayer, JM1
Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J1
Bandaranayake, RM; Heroux, A; Kakizawa, J; King, NM; Kolli, M; Nalivaika, EA; Schiffer, CA; Sugiura, W1
Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A1
de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C1
Nsanzabana, C; Rosenthal, PJ1
Amano, M; Ghosh, AK; Mitsuya, H; Osswald, HL; Rusere, LN; Schiltz, GE; Walters, DE1
Flaisigová, I; Günterová, J; Humpolíčková, J; Konvalinka, J; Majerová, T; Mašínová, E; Starková, J; Weber, J1
Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M1

Reviews

2 review(s) available for nelfinavir and darunavir

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Quality control of protease inhibitors.
    Journal of pharmaceutical sciences, 2008, Volume: 97, Issue:6

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides

2008

Trials

1 trial(s) available for nelfinavir and darunavir

ArticleYear
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Antiviral therapy, 2010, Volume: 15, Issue:8

    Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load

2010

Other Studies

24 other study(ies) available for nelfinavir and darunavir

ArticleYear
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles

2005
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
    Bioorganic & medicinal chemistry letters, 2006, Apr-01, Volume: 16, Issue:7

    Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides

2006
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Journal of medicinal chemistry, 2006, Aug-24, Volume: 49, Issue:17

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides

2006
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6

    Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication

2007
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9

    Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication

2007
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9

    Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine

2007
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10

    Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir

2007
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4

    Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage

2008
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4

    Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides

2008
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15

    Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation

2008
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides

2009
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8

    Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication

2010
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11

    Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides

2010
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:3

    Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication

2011
Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.
    Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5

    Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Cell Line; Dimerization; Drug Development; HIV Infections; HIV-1; Humans; Models, Molecular; Prodrugs

2020
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Proteins, 2009, May-15, Volume: 75, Issue:3

    Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides

2009
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
    Journal of molecular graphics & modelling, 2010, Volume: 28, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides

2010
The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
    Journal of virology, 2010, Volume: 84, Issue:19

    Topics: Amino Acid Sequence; Amino Acid Substitution; Catalytic Domain; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Genes, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Polymorphism, Genetic; Protein Conformation; Sequence Homology, Amino Acid; Sulfonamides; Thermodynamics

2010
HIV-1 protease mutations and protease inhibitor cross-resistance.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides

2010
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:11

    Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides

2011
Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.
    Organic & biomolecular chemistry, 2014, Sep-21, Volume: 12, Issue:35

    Topics: Antiviral Agents; Catalytic Domain; Cell Line; Darunavir; Drug Design; Drug Evaluation, Preclinical; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Kinetics; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Nelfinavir; Structure-Activity Relationship; Sulfonamides; Tyrosine

2014
Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation.
    Scientific reports, 2018, Jul-11, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Darunavir; Flow Cytometry; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Protein Precursors; Proteolysis

2018
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
    Scientific reports, 2020, 10-12, Volume: 10, Issue:1

    Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins

2020